Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
Understanding SARS-CoV-2 vaccine-induced antibody responses in varied antigenic and serological prior exposures can guide optimal vaccination strategies for enhanced immunogenicity. We evaluated spike (S)-directed IgG, IgM, and IgA antibody optical densities (ODs) and concentrations to the two-dose...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0303113 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849469953770520576 |
|---|---|
| author | Jennifer Serwanga Gerald Kevin Oluka Claire Baine Violet Ankunda Jackson Sembera Laban Kato Joseph Ssebwana Katende Geoffrey Odoch Betty Oliver Auma Ben Gombe COVID-19 Immunoprofiling Team Monica Musenero Pontiano Kaleebu |
| author_facet | Jennifer Serwanga Gerald Kevin Oluka Claire Baine Violet Ankunda Jackson Sembera Laban Kato Joseph Ssebwana Katende Geoffrey Odoch Betty Oliver Auma Ben Gombe COVID-19 Immunoprofiling Team Monica Musenero Pontiano Kaleebu |
| author_sort | Jennifer Serwanga |
| collection | DOAJ |
| description | Understanding SARS-CoV-2 vaccine-induced antibody responses in varied antigenic and serological prior exposures can guide optimal vaccination strategies for enhanced immunogenicity. We evaluated spike (S)-directed IgG, IgM, and IgA antibody optical densities (ODs) and concentrations to the two-dose ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine in 67 Ugandans, categorised by prior infection and baseline S-IgG histories: uninfected and S-IgG-negative (n = 12); previously infected yet S-IgG-negative (n = 17); and previously infected with S-IgG-positive status (n = 38). Antibody dynamics were compared across eight timepoints from baseline till nine months. S-IgG antibodies remained consistently potent across all groups. Individuals with prior infections maintained robust S-IgG levels, underscoring the endurance of hybrid immunity. In contrast, those without prior exposure experienced an initial surge in S-IgG after the primary dose but no subsequent significant increase post-boost. However, they reached levels parallel to the previously exposed groups. S-IgM levels remained moderate, while S-IgA persisted in individuals with prior antigen exposure. ChAdOx1-S, Covishield vaccine elicited robust and sustained antibody responses in recipients, irrespective of their initial immune profiles. Hybrid immunity showed higher responses, aligning with global observations. Early post-vaccination antibody levels could predict long-term immunity, particularly in individuals without virus exposure. These findings can inform vaccine strategies and pandemic management. |
| format | Article |
| id | doaj-art-97ffa7599c1441e4807481d7a29eb2bb |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-97ffa7599c1441e4807481d7a29eb2bb2025-08-20T03:25:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01197e030311310.1371/journal.pone.0303113Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.Jennifer SerwangaGerald Kevin OlukaClaire BaineViolet AnkundaJackson SemberaLaban KatoJoseph Ssebwana KatendeGeoffrey OdochBetty Oliver AumaBen GombeCOVID-19 Immunoprofiling TeamMonica MuseneroPontiano KaleebuUnderstanding SARS-CoV-2 vaccine-induced antibody responses in varied antigenic and serological prior exposures can guide optimal vaccination strategies for enhanced immunogenicity. We evaluated spike (S)-directed IgG, IgM, and IgA antibody optical densities (ODs) and concentrations to the two-dose ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine in 67 Ugandans, categorised by prior infection and baseline S-IgG histories: uninfected and S-IgG-negative (n = 12); previously infected yet S-IgG-negative (n = 17); and previously infected with S-IgG-positive status (n = 38). Antibody dynamics were compared across eight timepoints from baseline till nine months. S-IgG antibodies remained consistently potent across all groups. Individuals with prior infections maintained robust S-IgG levels, underscoring the endurance of hybrid immunity. In contrast, those without prior exposure experienced an initial surge in S-IgG after the primary dose but no subsequent significant increase post-boost. However, they reached levels parallel to the previously exposed groups. S-IgM levels remained moderate, while S-IgA persisted in individuals with prior antigen exposure. ChAdOx1-S, Covishield vaccine elicited robust and sustained antibody responses in recipients, irrespective of their initial immune profiles. Hybrid immunity showed higher responses, aligning with global observations. Early post-vaccination antibody levels could predict long-term immunity, particularly in individuals without virus exposure. These findings can inform vaccine strategies and pandemic management.https://doi.org/10.1371/journal.pone.0303113 |
| spellingShingle | Jennifer Serwanga Gerald Kevin Oluka Claire Baine Violet Ankunda Jackson Sembera Laban Kato Joseph Ssebwana Katende Geoffrey Odoch Betty Oliver Auma Ben Gombe COVID-19 Immunoprofiling Team Monica Musenero Pontiano Kaleebu Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles. PLoS ONE |
| title | Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles. |
| title_full | Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles. |
| title_fullStr | Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles. |
| title_full_unstemmed | Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles. |
| title_short | Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles. |
| title_sort | persistent and robust antibody responses to chadox1 s oxford astrazeneca chadox1 s covishield sars cov 2 vaccine observed in ugandans across varied baseline immune profiles |
| url | https://doi.org/10.1371/journal.pone.0303113 |
| work_keys_str_mv | AT jenniferserwanga persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT geraldkevinoluka persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT clairebaine persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT violetankunda persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT jacksonsembera persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT labankato persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT josephssebwanakatende persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT geoffreyodoch persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT bettyoliverauma persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT bengombe persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT covid19immunoprofilingteam persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT monicamusenero persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles AT pontianokaleebu persistentandrobustantibodyresponsestochadox1soxfordastrazenecachadox1scovishieldsarscov2vaccineobservedinugandansacrossvariedbaselineimmuneprofiles |